| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Urology | 10 | 2023 | 411 | 4.830 |
Why?
|
| Urinary Bladder | 20 | 2023 | 1162 | 2.920 |
Why?
|
| Urologic Surgical Procedures | 11 | 2024 | 299 | 2.190 |
Why?
|
| Vesico-Ureteral Reflux | 8 | 2020 | 433 | 2.010 |
Why?
|
| Urethra | 7 | 2021 | 407 | 1.840 |
Why?
|
| Spinal Dysraphism | 7 | 2024 | 179 | 1.820 |
Why?
|
| Urodynamics | 8 | 2020 | 349 | 1.780 |
Why?
|
| Urinary Bladder, Overactive | 3 | 2023 | 119 | 1.500 |
Why?
|
| Fibroins | 9 | 2018 | 59 | 1.420 |
Why?
|
| Silk | 7 | 2016 | 93 | 1.360 |
Why?
|
| Urinary Bladder, Neurogenic | 6 | 2024 | 176 | 1.320 |
Why?
|
| Telemedicine | 6 | 2023 | 3109 | 0.960 |
Why?
|
| Urinary Tract Infections | 4 | 2020 | 805 | 0.950 |
Why?
|
| Tissue Scaffolds | 13 | 2018 | 951 | 0.930 |
Why?
|
| Tissue Engineering | 8 | 2017 | 1893 | 0.900 |
Why?
|
| Hydronephrosis | 3 | 2011 | 274 | 0.880 |
Why?
|
| Botulinum Toxins, Type A | 2 | 2024 | 238 | 0.840 |
Why?
|
| Postoperative Care | 2 | 2020 | 1481 | 0.840 |
Why?
|
| Penile Induration | 5 | 2005 | 17 | 0.740 |
Why?
|
| Circumcision, Male | 1 | 2020 | 148 | 0.640 |
Why?
|
| Child | 38 | 2024 | 80969 | 0.580 |
Why?
|
| Nurse Practitioners | 1 | 2020 | 271 | 0.560 |
Why?
|
| Meningomyelocele | 2 | 2023 | 182 | 0.540 |
Why?
|
| Biocompatible Materials | 6 | 2018 | 1703 | 0.530 |
Why?
|
| Urologic Diseases | 2 | 2009 | 247 | 0.510 |
Why?
|
| Regeneration | 9 | 2018 | 1524 | 0.490 |
Why?
|
| Penis | 3 | 2020 | 210 | 0.420 |
Why?
|
| Urinary Bladder Diseases | 4 | 2018 | 167 | 0.400 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2015 | 365 | 0.370 |
Why?
|
| Myocytes, Smooth Muscle | 5 | 2013 | 703 | 0.370 |
Why?
|
| GATA6 Transcription Factor | 1 | 2010 | 54 | 0.350 |
Why?
|
| Urothelium | 3 | 2013 | 276 | 0.350 |
Why?
|
| Ureter | 2 | 2010 | 370 | 0.340 |
Why?
|
| GATA4 Transcription Factor | 1 | 2010 | 125 | 0.330 |
Why?
|
| Drug Resistance, Multiple | 1 | 2010 | 255 | 0.320 |
Why?
|
| Kidney Calices | 1 | 2009 | 26 | 0.320 |
Why?
|
| Replantation | 1 | 2010 | 145 | 0.320 |
Why?
|
| Urologic Surgical Procedures, Male | 3 | 2018 | 79 | 0.320 |
Why?
|
| Ureteral Obstruction | 1 | 2011 | 297 | 0.320 |
Why?
|
| Child, Preschool | 16 | 2024 | 42684 | 0.300 |
Why?
|
| Fetal Diseases | 2 | 2017 | 916 | 0.300 |
Why?
|
| Verapamil | 3 | 2003 | 242 | 0.300 |
Why?
|
| Humans | 80 | 2024 | 768887 | 0.300 |
Why?
|
| Diverticulum | 1 | 2009 | 137 | 0.290 |
Why?
|
| Nomograms | 1 | 2009 | 236 | 0.290 |
Why?
|
| Tretinoin | 1 | 2010 | 525 | 0.280 |
Why?
|
| Embryonic Stem Cells | 2 | 2013 | 1251 | 0.280 |
Why?
|
| Sexual Behavior | 2 | 2015 | 2200 | 0.270 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 2006 | 82 | 0.270 |
Why?
|
| Pain | 3 | 2020 | 5100 | 0.260 |
Why?
|
| Esophagoplasty | 2 | 2017 | 48 | 0.260 |
Why?
|
| Robotics | 3 | 2008 | 826 | 0.260 |
Why?
|
| Bladder Exstrophy | 3 | 2023 | 106 | 0.260 |
Why?
|
| Costs and Cost Analysis | 2 | 2023 | 1669 | 0.260 |
Why?
|
| Hypospadias | 2 | 2017 | 98 | 0.250 |
Why?
|
| Fetus | 1 | 2012 | 1882 | 0.240 |
Why?
|
| Anxiety | 1 | 2020 | 4677 | 0.240 |
Why?
|
| Infant | 11 | 2020 | 36541 | 0.240 |
Why?
|
| Male | 50 | 2024 | 365249 | 0.230 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2005 | 213 | 0.230 |
Why?
|
| Urinary Tract | 2 | 2023 | 305 | 0.220 |
Why?
|
| Durable Medical Equipment | 1 | 2023 | 23 | 0.220 |
Why?
|
| Laparoscopy | 4 | 2024 | 2055 | 0.220 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2010 | 843 | 0.220 |
Why?
|
| Priapism | 1 | 2003 | 28 | 0.220 |
Why?
|
| Fossil Fuels | 1 | 2023 | 53 | 0.210 |
Why?
|
| Pericardium | 2 | 2005 | 679 | 0.200 |
Why?
|
| Colpotomy | 1 | 2022 | 9 | 0.200 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2006 | 798 | 0.200 |
Why?
|
| Abdominal Neoplasms | 1 | 2003 | 287 | 0.190 |
Why?
|
| Genital Diseases, Female | 1 | 2023 | 192 | 0.190 |
Why?
|
| Mammary Arteries | 1 | 2002 | 82 | 0.190 |
Why?
|
| Erectile Dysfunction | 1 | 2005 | 445 | 0.190 |
Why?
|
| Kidney Diseases | 2 | 2010 | 2100 | 0.190 |
Why?
|
| Female | 43 | 2024 | 397464 | 0.190 |
Why?
|
| Clitoris | 1 | 2021 | 35 | 0.190 |
Why?
|
| Fecal Incontinence | 1 | 2024 | 246 | 0.180 |
Why?
|
| Ambulatory Care | 2 | 2022 | 2783 | 0.180 |
Why?
|
| Sex Reassignment Procedures | 1 | 2021 | 72 | 0.180 |
Why?
|
| Thoracic Outlet Syndrome | 1 | 2002 | 97 | 0.170 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2011 | 2250 | 0.170 |
Why?
|
| Spermatic Cord Torsion | 2 | 2013 | 72 | 0.170 |
Why?
|
| Urination Disorders | 2 | 2012 | 238 | 0.170 |
Why?
|
| Urethral Diseases | 2 | 2018 | 52 | 0.160 |
Why?
|
| Ambulatory Care Facilities | 3 | 2022 | 941 | 0.160 |
Why?
|
| Calcium Channel Blockers | 1 | 2002 | 691 | 0.160 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2005 | 3200 | 0.160 |
Why?
|
| Carbon Dioxide | 1 | 2023 | 1149 | 0.160 |
Why?
|
| Sex Reassignment Surgery | 1 | 2022 | 165 | 0.160 |
Why?
|
| Retrospective Studies | 19 | 2024 | 81892 | 0.150 |
Why?
|
| Absenteeism | 1 | 2020 | 247 | 0.150 |
Why?
|
| Exploratory Behavior | 1 | 2019 | 276 | 0.150 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2002 | 350 | 0.150 |
Why?
|
| Orchiopexy | 1 | 2017 | 21 | 0.150 |
Why?
|
| Videoconferencing | 1 | 2020 | 209 | 0.140 |
Why?
|
| Stem Cells | 2 | 2009 | 3540 | 0.140 |
Why?
|
| Transsexualism | 1 | 2021 | 210 | 0.140 |
Why?
|
| Environment | 1 | 2023 | 1125 | 0.140 |
Why?
|
| Spinal Cord Injuries | 2 | 2015 | 929 | 0.140 |
Why?
|
| Young Adult | 6 | 2023 | 60110 | 0.140 |
Why?
|
| Hospitals, Pediatric | 3 | 2024 | 1876 | 0.140 |
Why?
|
| Adolescent | 13 | 2024 | 89247 | 0.130 |
Why?
|
| Hydrocephalus | 1 | 2023 | 770 | 0.130 |
Why?
|
| Outpatients | 1 | 2023 | 1604 | 0.130 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2020 | 640 | 0.120 |
Why?
|
| Animals | 26 | 2022 | 169408 | 0.120 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2017 | 1767 | 0.120 |
Why?
|
| Rats | 9 | 2015 | 23847 | 0.120 |
Why?
|
| Awards and Prizes | 1 | 2019 | 365 | 0.120 |
Why?
|
| Inosine | 1 | 2015 | 129 | 0.120 |
Why?
|
| Pandemics | 4 | 2023 | 8745 | 0.120 |
Why?
|
| Chest Pain | 1 | 2002 | 1101 | 0.120 |
Why?
|
| Bombyx | 2 | 2013 | 58 | 0.120 |
Why?
|
| Electromyography | 1 | 2020 | 1402 | 0.120 |
Why?
|
| Urogenital Abnormalities | 1 | 2017 | 255 | 0.120 |
Why?
|
| Cost Savings | 1 | 2020 | 915 | 0.120 |
Why?
|
| Hyperglycemia | 1 | 2003 | 1389 | 0.120 |
Why?
|
| Piperazines | 1 | 2005 | 2553 | 0.110 |
Why?
|
| Cystoscopy | 2 | 2011 | 132 | 0.110 |
Why?
|
| Coronary Artery Bypass | 1 | 2003 | 2194 | 0.110 |
Why?
|
| Travel | 1 | 2020 | 805 | 0.110 |
Why?
|
| Referral and Consultation | 2 | 2023 | 3626 | 0.110 |
Why?
|
| Prostate | 1 | 2022 | 1781 | 0.110 |
Why?
|
| Kidney Neoplasms | 2 | 2011 | 4300 | 0.110 |
Why?
|
| Risk Assessment | 3 | 2010 | 24330 | 0.110 |
Why?
|
| Clinical Clerkship | 1 | 2019 | 569 | 0.110 |
Why?
|
| Recurrence | 2 | 2019 | 8512 | 0.110 |
Why?
|
| Esophageal Neoplasms | 1 | 2003 | 1674 | 0.100 |
Why?
|
| Models, Animal | 3 | 2014 | 2123 | 0.100 |
Why?
|
| Digestive System Abnormalities | 1 | 2012 | 49 | 0.100 |
Why?
|
| Diagnostic Techniques, Urological | 1 | 2011 | 29 | 0.100 |
Why?
|
| Syringomyelia | 1 | 2012 | 67 | 0.100 |
Why?
|
| Feasibility Studies | 3 | 2019 | 5323 | 0.100 |
Why?
|
| Computer-Assisted Instruction | 1 | 2015 | 366 | 0.100 |
Why?
|
| Fever | 1 | 2019 | 1620 | 0.090 |
Why?
|
| Immunohistochemistry | 5 | 2014 | 11119 | 0.090 |
Why?
|
| Particulate Matter | 1 | 2023 | 2607 | 0.090 |
Why?
|
| Muscle, Smooth | 4 | 2013 | 931 | 0.090 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 3538 | 0.090 |
Why?
|
| Esophagus | 1 | 2017 | 1043 | 0.090 |
Why?
|
| Testosterone | 2 | 2021 | 2494 | 0.090 |
Why?
|
| Faculty, Medical | 1 | 2019 | 1225 | 0.090 |
Why?
|
| Infant, Newborn | 5 | 2020 | 26394 | 0.090 |
Why?
|
| Disease Models, Animal | 8 | 2022 | 18366 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2019 | 8742 | 0.090 |
Why?
|
| Cohort Studies | 4 | 2020 | 41800 | 0.090 |
Why?
|
| Receptors, CCR2 | 1 | 2011 | 216 | 0.090 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2010 | 294 | 0.080 |
Why?
|
| Neural Tube Defects | 1 | 2012 | 255 | 0.080 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2010 | 221 | 0.080 |
Why?
|
| Polyglycolic Acid | 1 | 2010 | 408 | 0.080 |
Why?
|
| Remission, Spontaneous | 1 | 2009 | 385 | 0.080 |
Why?
|
| Arthritis, Experimental | 1 | 2011 | 293 | 0.080 |
Why?
|
| Treatment Outcome | 10 | 2023 | 65485 | 0.080 |
Why?
|
| Biofeedback, Psychology | 1 | 2009 | 117 | 0.080 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2013 | 835 | 0.080 |
Why?
|
| Patient Selection | 1 | 2020 | 4265 | 0.080 |
Why?
|
| Adoptive Transfer | 1 | 2011 | 824 | 0.080 |
Why?
|
| Medical Records | 1 | 2014 | 1411 | 0.080 |
Why?
|
| Multipotent Stem Cells | 1 | 2009 | 201 | 0.080 |
Why?
|
| Infertility | 1 | 2015 | 654 | 0.080 |
Why?
|
| Fluorocarbons | 1 | 2013 | 506 | 0.070 |
Why?
|
| Urolithiasis | 1 | 2009 | 125 | 0.070 |
Why?
|
| Adult | 12 | 2022 | 223818 | 0.070 |
Why?
|
| Algorithms | 3 | 2020 | 14199 | 0.070 |
Why?
|
| Urinary Diversion | 1 | 2008 | 137 | 0.070 |
Why?
|
| Likelihood Functions | 1 | 2010 | 993 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2017 | 8200 | 0.070 |
Why?
|
| Prospective Studies | 4 | 2020 | 54950 | 0.070 |
Why?
|
| Massachusetts | 1 | 2020 | 8888 | 0.070 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2007 | 79 | 0.070 |
Why?
|
| Nephrectomy | 1 | 2011 | 949 | 0.060 |
Why?
|
| Postoperative Complications | 3 | 2005 | 15889 | 0.060 |
Why?
|
| Wound Healing | 1 | 2017 | 2815 | 0.060 |
Why?
|
| Patient Satisfaction | 3 | 2022 | 3489 | 0.060 |
Why?
|
| Mice | 8 | 2022 | 82074 | 0.060 |
Why?
|
| Cells, Cultured | 4 | 2010 | 19023 | 0.060 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 381 | 0.060 |
Why?
|
| Rats, Wistar | 2 | 2006 | 1890 | 0.060 |
Why?
|
| 3',5'-Cyclic-GMP Phosphodiesterases | 1 | 2005 | 56 | 0.060 |
Why?
|
| Medicare | 1 | 2023 | 6888 | 0.060 |
Why?
|
| Injections, Intralesional | 2 | 2003 | 280 | 0.060 |
Why?
|
| Double-Blind Method | 1 | 2019 | 12469 | 0.060 |
Why?
|
| Receptors, CCR5 | 1 | 2007 | 491 | 0.060 |
Why?
|
| Rabbits | 3 | 2018 | 4774 | 0.060 |
Why?
|
| Caveolae | 1 | 2004 | 54 | 0.060 |
Why?
|
| Swine | 4 | 2018 | 5998 | 0.060 |
Why?
|
| Quantum Dots | 1 | 2006 | 168 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2003 | 5892 | 0.060 |
Why?
|
| Cystostomy | 1 | 2004 | 25 | 0.060 |
Why?
|
| Androgens | 2 | 2022 | 1285 | 0.060 |
Why?
|
| Neonatal Screening | 1 | 2008 | 618 | 0.060 |
Why?
|
| Cicatrix | 1 | 2010 | 799 | 0.060 |
Why?
|
| Organ Culture Techniques | 1 | 2006 | 796 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2019 | 4859 | 0.050 |
Why?
|
| Colostomy | 1 | 2024 | 106 | 0.050 |
Why?
|
| Genes, erbB-2 | 1 | 2004 | 162 | 0.050 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 1794 | 0.050 |
Why?
|
| Enema | 1 | 2024 | 141 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2011 | 13020 | 0.050 |
Why?
|
| Observer Variation | 1 | 2009 | 2623 | 0.050 |
Why?
|
| Intestinal Mucosa | 1 | 2014 | 3047 | 0.050 |
Why?
|
| Image Enhancement | 1 | 2013 | 2898 | 0.050 |
Why?
|
| Kidney Calculi | 1 | 2007 | 469 | 0.050 |
Why?
|
| Pluripotent Stem Cells | 1 | 2009 | 810 | 0.050 |
Why?
|
| Injections, Intramuscular | 1 | 2024 | 556 | 0.050 |
Why?
|
| Pituitary Diseases | 1 | 2003 | 136 | 0.050 |
Why?
|
| Self Report | 1 | 2014 | 3773 | 0.050 |
Why?
|
| Sulfones | 1 | 2005 | 448 | 0.050 |
Why?
|
| Neuromuscular Agents | 1 | 2024 | 148 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2006 | 2018 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 7460 | 0.050 |
Why?
|
| Penile Prosthesis | 1 | 2001 | 33 | 0.050 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2023 | 187 | 0.050 |
Why?
|
| Purines | 1 | 2005 | 615 | 0.050 |
Why?
|
| Prolactin | 1 | 2003 | 627 | 0.050 |
Why?
|
| Decision Support Techniques | 1 | 2011 | 2008 | 0.050 |
Why?
|
| Chronic Disease | 2 | 2023 | 9384 | 0.050 |
Why?
|
| Pregnancy | 4 | 2023 | 30175 | 0.050 |
Why?
|
| Registries | 1 | 2017 | 8384 | 0.050 |
Why?
|
| Hospital Charges | 1 | 2003 | 351 | 0.050 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 1602 | 0.050 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2013 | 1891 | 0.050 |
Why?
|
| Sex Factors | 1 | 2015 | 10641 | 0.050 |
Why?
|
| Models, Biological | 1 | 2017 | 9499 | 0.050 |
Why?
|
| Metaplasia | 1 | 2022 | 326 | 0.050 |
Why?
|
| Pituitary Gland | 1 | 2003 | 634 | 0.040 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 7472 | 0.040 |
Why?
|
| Forecasting | 1 | 2009 | 2946 | 0.040 |
Why?
|
| Follow-Up Studies | 4 | 2011 | 39394 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2013 | 14751 | 0.040 |
Why?
|
| Time Factors | 3 | 2020 | 40266 | 0.040 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2013 | 4077 | 0.040 |
Why?
|
| Transforming Growth Factor beta | 2 | 2004 | 2004 | 0.040 |
Why?
|
| Dendritic Cells | 1 | 2011 | 2748 | 0.040 |
Why?
|
| Flow Cytometry | 1 | 2010 | 5905 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2010 | 3714 | 0.040 |
Why?
|
| Cadaver | 1 | 2003 | 1366 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 5801 | 0.040 |
Why?
|
| Equipment Design | 1 | 2007 | 3529 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 1 | 2006 | 2635 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2003 | 13593 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2003 | 1836 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 1 | 2006 | 6131 | 0.040 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 11934 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 3629 | 0.040 |
Why?
|
| Radiography | 1 | 2008 | 6991 | 0.040 |
Why?
|
| Caustics | 1 | 2017 | 33 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2011 | 22381 | 0.040 |
Why?
|
| Hypogonadism | 1 | 2003 | 805 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2015 | 22294 | 0.030 |
Why?
|
| Hospital Costs | 1 | 2003 | 959 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2011 | 20776 | 0.030 |
Why?
|
| Kidney Pelvis | 1 | 2017 | 195 | 0.030 |
Why?
|
| Vagina | 1 | 2022 | 848 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2001 | 1209 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 20244 | 0.030 |
Why?
|
| Prognosis | 2 | 2009 | 30044 | 0.030 |
Why?
|
| Synaptophysin | 1 | 2015 | 140 | 0.030 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2011 | 3780 | 0.030 |
Why?
|
| Transplantation, Heterologous | 1 | 2003 | 2395 | 0.030 |
Why?
|
| Risk Factors | 3 | 2010 | 74971 | 0.030 |
Why?
|
| Muscle Contraction | 2 | 2013 | 1209 | 0.030 |
Why?
|
| Biomedical Research | 1 | 2009 | 3463 | 0.030 |
Why?
|
| Cross Infection | 1 | 2003 | 1425 | 0.030 |
Why?
|
| TRPV Cation Channels | 1 | 2015 | 244 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 2003 | 1546 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2003 | 1321 | 0.030 |
Why?
|
| Neurofilament Proteins | 1 | 2015 | 337 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2010 | 7885 | 0.030 |
Why?
|
| Length of Stay | 2 | 2007 | 6525 | 0.030 |
Why?
|
| Receptor, erbB-2 | 1 | 2004 | 2606 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2008 | 8095 | 0.030 |
Why?
|
| Urinary Calculi | 1 | 2013 | 90 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2015 | 457 | 0.030 |
Why?
|
| Predictive Value of Tests | 2 | 2020 | 15471 | 0.030 |
Why?
|
| Signal Transduction | 3 | 2011 | 23652 | 0.020 |
Why?
|
| Internal Medicine | 1 | 2019 | 1064 | 0.020 |
Why?
|
| Cause of Death | 1 | 2023 | 3721 | 0.020 |
Why?
|
| Epidermal Growth Factor | 2 | 2005 | 697 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 26384 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2013 | 945 | 0.020 |
Why?
|
| Atherosclerosis | 1 | 2007 | 3431 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2003 | 9682 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2006 | 10486 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 15955 | 0.020 |
Why?
|
| Collagen Type II | 1 | 2011 | 151 | 0.020 |
Why?
|
| Middle Aged | 6 | 2005 | 223740 | 0.020 |
Why?
|
| Incidence | 1 | 2008 | 21545 | 0.020 |
Why?
|
| Sacrum | 1 | 2012 | 275 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 2017 | 1274 | 0.020 |
Why?
|
| Nephrons | 1 | 2011 | 168 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2011 | 624 | 0.020 |
Why?
|
| Medicaid | 1 | 2023 | 2843 | 0.020 |
Why?
|
| Stress, Mechanical | 2 | 2005 | 1680 | 0.020 |
Why?
|
| Anal Canal | 1 | 2012 | 375 | 0.020 |
Why?
|
| Hospitals | 1 | 2023 | 3903 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2019 | 2784 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2003 | 6434 | 0.020 |
Why?
|
| Ultrasonography | 2 | 2013 | 6001 | 0.020 |
Why?
|
| Aged | 5 | 2023 | 171790 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2004 | 8664 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2011 | 855 | 0.020 |
Why?
|
| Parkinson Disease | 1 | 2002 | 2896 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2005 | 4593 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2005 | 1658 | 0.020 |
Why?
|
| Endoscopy | 1 | 2017 | 1862 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2011 | 494 | 0.020 |
Why?
|
| Rectum | 1 | 2012 | 900 | 0.020 |
Why?
|
| Interleukin-6 | 2 | 2007 | 3233 | 0.020 |
Why?
|
| United States | 2 | 2024 | 73180 | 0.020 |
Why?
|
| Ileum | 1 | 2008 | 558 | 0.020 |
Why?
|
| Disease Progression | 1 | 2002 | 13677 | 0.020 |
Why?
|
| Fibroblast Growth Factor 9 | 1 | 2004 | 13 | 0.020 |
Why?
|
| Receptor, PAR-2 | 1 | 2004 | 33 | 0.010 |
Why?
|
| Muscle Relaxation | 1 | 2005 | 138 | 0.010 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2004 | 81 | 0.010 |
Why?
|
| Pediatrics | 1 | 2019 | 3628 | 0.010 |
Why?
|
| Empty Sella Syndrome | 1 | 2003 | 14 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2004 | 254 | 0.010 |
Why?
|
| Chicago | 1 | 2004 | 255 | 0.010 |
Why?
|
| Drug Administration Routes | 1 | 2003 | 151 | 0.010 |
Why?
|
| Neurofibromin 1 | 1 | 2004 | 190 | 0.010 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 321 | 0.010 |
Why?
|
| Appendix | 1 | 2004 | 109 | 0.010 |
Why?
|
| Suture Techniques | 1 | 2008 | 779 | 0.010 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2004 | 344 | 0.010 |
Why?
|
| Electricity | 1 | 2003 | 176 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2004 | 617 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2004 | 599 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2011 | 2323 | 0.010 |
Why?
|
| Oligonucleotides | 1 | 2004 | 563 | 0.010 |
Why?
|
| Inflammation | 2 | 2014 | 10869 | 0.010 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2004 | 642 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 3411 | 0.010 |
Why?
|
| Contrast Media | 1 | 2013 | 5334 | 0.010 |
Why?
|
| RNA, Messenger | 2 | 2005 | 12809 | 0.010 |
Why?
|
| Epinephrine | 1 | 2003 | 794 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 2414 | 0.010 |
Why?
|
| Physical Examination | 1 | 2005 | 1262 | 0.010 |
Why?
|
| Gene Amplification | 1 | 2004 | 1099 | 0.010 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2004 | 847 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2007 | 2709 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2003 | 2299 | 0.010 |
Why?
|
| Cell Line | 1 | 2013 | 15603 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2011 | 5544 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2004 | 2525 | 0.010 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2011 | 3116 | 0.010 |
Why?
|
| Aortic Valve | 1 | 2007 | 1969 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2004 | 2437 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2004 | 3811 | 0.010 |
Why?
|
| Binding Sites | 1 | 2004 | 6023 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2003 | 36861 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2011 | 14485 | 0.010 |
Why?
|
| Pituitary Neoplasms | 1 | 2003 | 1326 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 9564 | 0.010 |
Why?
|
| Prosthesis Design | 1 | 2001 | 2126 | 0.010 |
Why?
|
| Adenoma | 1 | 2003 | 2164 | 0.010 |
Why?
|
| Computational Biology | 1 | 2004 | 3562 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 7214 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2004 | 7609 | 0.010 |
Why?
|
| Age Factors | 1 | 2007 | 18454 | 0.010 |
Why?
|